LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price ...

We are thrilled to have John join the Nurix team as we prepare to launch our pivotal clinical program for NX-5948 in chronic lymphocytic leukemia and potentially other B-cell malignancies,” said ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

As investors react to an ever-changing political climate, Ash Shehata from KPMG explains what factors they're paying ...

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...